Schedule of Pharmaceutical Benefits - 1 December 2017 update

PBAC

1 December 2017 - The December 2017 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The December issue of the Schedule includes a number of minor new/revised listings:

  • Abiraterone acetate (Zytiga) - new strength
  • Eribulin mesylate (Halaven) - new indication
  • Etanercept (Brenzys) - restriction change
  • Ibrutinib (Imbruvica) - new medicine
  • Mesalazine (Azacol) - new strength
  • Milk powder - lactose intolerance formula (S-26 Original Li) - new formulation
  • Vitamins, minerals and trace elements formula (Phlexy Vits) - new combination product

Read Summary of Changes

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Listing , Australia